Premium
Letter: cytokeratin‐18 as a biomarker of hepatocellular carcinoma regression after transarterial chemoembolization
Author(s) -
He Z.H.,
He W.R.,
Wu L.L.,
Zhao C.,
Peng N.F.,
Ahir B.K.,
Lu C.Y.
Publication year - 2017
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/apt.13820
Subject(s) - medicine , hepatocellular carcinoma , cytokeratin , carcinoma , response evaluation criteria in solid tumors , oncology , biomarker , chemotherapy , immunohistochemistry , biochemistry , chemistry , progressive disease